Al Kanaani Zaina, Mahmud Sarwat, Kouyoumjian Silva P, Abu-Raddad Laith J
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Qatar Foundation - Education City, PO Box 24144, Doha, Qatar.
Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY, USA.
R Soc Open Sci. 2018 Apr 11;5(4):180257. doi: 10.1098/rsos.180257. eCollection 2018 Apr.
To characterize hepatitis C virus (HCV) epidemiology in Pakistan and estimate the pooled mean HCV antibody prevalence in different risk populations, we systematically reviewed all available records of HCV incidence and/or prevalence from 1989 to 2016, as informed by the Cochrane Collaboration Handbook. This systematic review was reported following the PRISMA guidelines. Populations were classified into six categories based on the risk of exposure to HCV infection. Meta-analyses were performed using DerSimonian and Laird random-effects models with inverse variance weighting. The search identified one HCV incidence study and 341 prevalence measures/strata. Meta-analyses estimated the pooled mean HCV prevalence at 6.2% among the general population, 34.5% among high-risk clinical populations, 12.8% among populations at intermediate risk, 16.9% among special clinical populations, 55.9% among populations with liver-related conditions and 53.6% among people who inject drugs. Most reported risk factors in analytical epidemiologic studies related to healthcare procedures. Pakistan is enduring an HCV epidemic of historical proportions-one in every 20 Pakistanis is infected. HCV plays a major role in liver disease burden in this country, and HCV prevalence is high in all-risk populations. Most transmission appears to be driven by healthcare procedures. HCV treatment and prevention must become a national priority.
为了描述巴基斯坦丙型肝炎病毒(HCV)的流行病学特征,并估计不同风险人群中HCV抗体的合并平均流行率,我们按照Cochrane协作手册的指导,系统回顾了1989年至2016年期间所有可用的HCV发病率和/或流行率记录。本系统评价按照PRISMA指南进行报告。根据接触HCV感染的风险将人群分为六类。采用DerSimonian和Laird随机效应模型及逆方差加权法进行Meta分析。检索共识别出1项HCV发病率研究和341项流行率测量/分层。Meta分析估计,普通人群中HCV的合并平均流行率为6.2%,高危临床人群中为34.5%,中等风险人群中为12.8%,特殊临床人群中为16.9%,患有肝脏相关疾病的人群中为55.9%,注射毒品者中为53.6%。分析性流行病学研究中报告的大多数风险因素与医疗程序有关。巴基斯坦正遭受着历史上规模巨大的HCV流行——每20名巴基斯坦人中就有1人感染。HCV在该国肝脏疾病负担中起主要作用,且在所有风险人群中HCV流行率都很高。大多数传播似乎是由医疗程序驱动的。HCV治疗和预防必须成为国家优先事项。